As of now, there is no cure for idiopathic pulmonary fibrosis (IPF). However, there OFEV® (nintedanib).is an IPF treatment called
In 3 out of 3 medical studies, OFEV capsules were proven to slow the decline in lung function by about 50%. This was determined by testing a patient's forced vital capacity, or FVC, after 1 year of therapy. FVC measurement is one of the ways the progressionof IPF is measured.
Lung function declines at different rates in different people. Some may progress rapidly while others may remain the same for long periods of time. Some people may experience "acute exacerbations." These attacks are a sudden and often permanent worsening of the disease. They can have many causes. Your healthcare team will determine if the episode is caused by IPF.
The chance of having an acute exacerbation during a 1-year period was significantly reduced in patients taking OFEV compared with those taking placebo in 2 out of 3 medical studies.
In a medical study, OFEV patients were 80% less likely to have an acute exacerbation versus placebo patients (7.3% vs 1.5%, respectively, with an absolute difference of 5.8%).
The 2 trials showing a benefit had similar results. The remaining trial showed no effect of OFEV on acute exacerbations.
OFEV is a prescription medicine designed to work for people with IPF by blocking the effects of some of the substances that are involved in the scarring of the lungs.
Talk to your doctor to see if OFEV is right for you.
OFEV can cause harm, birth defects or death to an unborn baby. Women should not become pregnant while taking OFEV. Women who are able to become pregnant should have a pregnancy test before starting treatment and should use birth control during and for at least 3 months after your last dose. If you become pregnant while taking OFEV, tell your doctor right away.